neobyRNT Health Insights

Superintelligence,
scrubbed in.

The AI co-pilot inside every interventional procedure. At the table for the coronary, the colon, the bronchus and the bile duct: it sees every frame, measures every lumen, and speaks only when it matters.

Request a demo →Watch the co-pilot
ListeningEvery lumen, lit.
Vision

It sees every frame.

Not one procedure. Millions of them.

Annotated by the physicians who perform them.

Illustrative, generated imagery · not patient data

1Frames learned from
Upper GI · AntrumWhite light · withdrawal
30 fpsFrame 01,284
Illustrative · generated image
Co-pilot · endoscopy

A co-pilot that waits for the pause.

Watching
  1. Withdrawal in progress. Antrum, white light.
  2. Subtle elevation, greater curvature. Flagged in the margin.
  3. Scope moving. Holding until the view is steady.
  4. View steady. Assessing across 42 frames.
  5. Suspicious area · conf 0.94 · frames 1,284–1,326.
  6. Your call, doctor.
Confidence · last 90 frames

Illustrative scenario on a generated image.

Platform

Every modality in.

One intelligence.

Every lumen out.

The stakes

The lesion was on the screen. Did anyone see it?

25%

of early oesophageal cancer lesions are missed at endoscopy

18%

of early gastric cancer lesions are missed at endoscopy

1 in 4

cancer cases worldwide is gastrointestinal

1 in 3

cancer deaths worldwide is gastrointestinal

Found late20%
Found early90%

Five-year survival. The distance between those bars is a few seconds of attention.

Published epidemiology, not neo performance data. Miss rates are upper bounds.

Doctrine

Superhuman perception. Human authority.

i.

The operator decides. Always.

neo flags, measures and recommends. It never acts on the patient, and nothing it shows reads as an instruction.

ii.

Never on the lesion.

Overlays live in the margins of the image. Nothing neo draws covers the region the operator is looking at.

iii.

Speak in the pause.

Findings surface between acts: after an injection, at the end of a pullback, as the scope withdraws.

iv.

Every number carries its proof.

Unit, confidence and source frame travel with every value. A number without provenance is not shown.

v.

Silence is a finding.

When nothing is wrong, neo shows one steady aqua line. Calm is information too.

The platform

One intelligence, four layers.

From the data it learns on to the console beside the operator. Each layer carries its own regulatory status, stated plainly.

In the procedure roomA live co-pilot on the console.

Real-time detection of subtle early gastric and oesophageal cancers during white-light endoscopy, and angiography-derived physiology in the cath lab.

Upper GI · 2× FDA Breakthrough DesignationCath lab · in development

Foundation modelLearns from every frame.

Endoscopy video, and co-registered angiography, IVUS, OCT and FFR, annotated by the physicians who perform these procedures.

In development

Data foundryEvery frame, accounted for.

Procedures become linked, de-identified, labelled records, with a rights ledger for every frame.

In development

SimulationRehearsal before the room.

The intelligence rehearses thousands of procedures before it enters a real room. First room: the cath lab.

In development
Every lumen

Every lumen is a candidate. None are announcements.

Upper GIShipping module
CoronaryIn development
IntravascularIn development
Structural heartIn development
NeurovascularIn development
Lower GIPasses the test
BronchialPasses the test
Peripheral vascularPasses the test
The record

Where we stand.

US FDA Breakthrough Device Designation, granted May 2024FDA · May 2024

Breakthrough Device Designation for early gastric cancer detection

US FDA Breakthrough Device Designation, granted December 2024FDA · Dec 2024

Breakthrough Device Designation for early oesophageal cancer detection

BSI ISO 13485 certifiedISO 13485 ↗

ISO 13485:2016 and EN ISO 13485, certified by BSI. Certificate MD 839871.

CDSCO, Government of IndiaCDSCO · MD-13

Test licence, India, granted July 2024. Registered prospective study live at Fortis.

In the press

The record, as others wrote it.

BusinessWire India ↗RNT Health Insights receives FDA Breakthrough Device Designation for its early gastric cancer detection toolBioSpectrum India ↗Second US FDA Breakthrough Device Designation, for the oesophageal cancer detection toolFortune India ↗Pfizer offers grant and incubation support to 14 Indian health-tech startups under its INDovation programmeThe Economic Times ↗Nikhil Kamath unveils the first 15 grantees of his WTFundMedTech Innovator ↗Named to the MedTech Innovator Asia Pacific AcceleratorThe Economic Times ↗Pfizer to fund six startups through its INDovation programme for healthcare
Backed by

Hospitals, institutes and programmes that believed early.

Contact

The future of the procedure room
is already in it.

Demos, clinical collaboration, partnershipscontact@rntinsights.com
Corporate officeFirst Floor, Aeren Building, Plot 14, Rajiv Gandhi Chandigarh Technology Park, Chandigarh 160101, India
FollowLinkedIn ↗